Literature DB >> 6271103

Replication of poliovirus and measles virus in cultures of human lymphoblastoid and of Burkitt lymphoma cell lines.

A Fagraeus, M Böttiger, L Heller, E Norrby.   

Abstract

Poliovirus type 1 replicated in 4 different human lymphoblastoid cell lines (LBL) transformed in vitro by EBV virus or isolated from cases of mononucleosis. Maximum virus titers were reached 2--4 days after inoculation. There was a decrease in percentage of viable cells in the infected cultures but a considerable fraction of cells was not destroyed by virus replication. A persistent low grade replication of virus was observed and demonstrable during 56 days after inoculation in one LBL cell line. Presumably a small fraction of cells supporting virus replication is continuously recruited from refractory cells. No virus propagation was demonstrable in 4 Burkitt lymphoma (BL) cell lines. Measles virus grew efficiently in both types of cell lines. Using indirect immunofluorescent technique poliovirus and measles virus antigen could be demonstrated in the cytoplasm of LBL cells in parallel with disappearance of F-actin containing microvilli.

Entities:  

Mesh:

Year:  1981        PMID: 6271103     DOI: 10.1007/bf01317338

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

1.  Reactivity of smooth-muscle antibodies, surface ultrastructure, and mobility in cells of human hematopoietic cell lines.

Authors:  A Fagraeus; K Nilsson; K Lidman; R Norberg
Journal:  J Natl Cancer Inst       Date:  1975-10       Impact factor: 13.506

2.  MULTIPLICATION OF POLIOVIRUS TYPE I IN PREPARATIONS OF HUMAN LEUKOCYTES AND ITS INHIBITION BY INTERFERON.

Authors:  I GRESSER; C CHANY
Journal:  J Immunol       Date:  1964-06       Impact factor: 5.422

Review 3.  Classification and biological nature of established human hematopoietic cell lines.

Authors:  K Nilsson; J Pontén
Journal:  Int J Cancer       Date:  1975-02-15       Impact factor: 7.396

4.  Effects of purified measles virus components on proliferating human lymphocytes.

Authors:  B Zweiman; R P Lisak; D Waters; H Koprowski
Journal:  Cell Immunol       Date:  1979-10       Impact factor: 4.868

5.  Actin filaments in paramyxovirus-infected human fibroblasts studied by indirect immunofluorescence.

Authors:  A Fagraeus; D L Tyrrell; R Norberg; E Norrby
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

Review 6.  Participation of lymphocytes in viral infections.

Authors:  E F Wheelock; S T Toy
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

7.  Replication and persistence of measles virus in defined subpopulations of human leukocytes.

Authors:  B S Joseph; P W Lampert; M B Oldstone
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

8.  Replication of mumps virus in human leukocyte cultures.

Authors:  H Duc-Nguyen; W Henle
Journal:  J Bacteriol       Date:  1966-07       Impact factor: 3.490

9.  Complementation analysis of measles virus mutants isolated from persistently infected lymphoblastoid cell lines.

Authors:  G Ju; M Birrer; S Udem; B R Bloom
Journal:  J Virol       Date:  1980-03       Impact factor: 5.103

10.  Virus replication and high-titered interferon production in human leukocyte cultures inoculated with Newcastle disease virus.

Authors:  E F Wheelock
Journal:  J Bacteriol       Date:  1966-11       Impact factor: 3.490

View more
  3 in total

1.  Isolation and characterization of HeLa cell lines blocked at different steps in the poliovirus life cycle.

Authors:  G Kaplan; A Levy; V R Racaniello
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

2.  Measles virus-induced disruption of the glial-fibrillary-acidic protein cytoskeleton in an astrocytoma cell line (U-251).

Authors:  W P Duprex; S McQuaid; B K Rima
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Susceptibility of human bone marrow cells and hematopoietic cell lines to coxsackievirus B3 infection.

Authors:  T Vuorinen; R Vainionpää; R Vanharanta; T Hyypiä
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.